sponsored
PatientsVille.com Logo

PatientsVille

Pristiq Medical Research Studies

Up-to-date List of Pristiq Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Pristiq Medical Research Studies

Rank Status Study
1 Recruiting Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Conditions: Dysthymic Disorder;   Dysthymia;   Chronic Depressive Disorder
Interventions: Drug: Desvenlafaxine;   Drug: Placebo
Outcome Measures: Hamilton Rating Scale for Depression - 24 item version (HDRS);   Clinical Global Improvement Scale (CGI-I);   Cornell Dysthymia Rating Scale (CDRS);   Quick Inventory of Depressive Symptomatology-Self-Rated version (QIDS-SR);   Beck Depression Inventory (BDI);   Columbia Suicide Severity Rating Scale (C-SSRS; Posner, et al., 2007)
2 Recruiting Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
Conditions: Major Depressive Disorder;   Vasomotor Symptoms
Intervention: Drug: desvenlafaxine succinate
Outcome Measure: Safety assessments as measured by evaluating any reported adverse events, scheduled physical examinations and vital signs assessments.
3 Unknown  Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
Conditions: Major Depressive Disorder;   Menopausal Staging and Vasomotor Symptoms (for Females)
Intervention: Drug: Desvenlafaxine Succinate
Outcome Measures: Effects of desvenlafaxine succinate (DVS) on brain structure and activation in midlife men and women with MDD.;   Changes in brain activity;   Changes in menopause-related symptoms among females
4 Not yet recruiting Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression
Condition: Vascular Depression
Intervention: Drug: Desvenlafaxine Succinate
Outcome Measure: Depressive Symptoms
5 Recruiting Omega 3 FA Supplements as Augmentation in the Treatment of Depression
Conditions: Major Depression;   Cancer;   Diabetes;   Cardiovascular Diseases
Interventions: Drug: Desvenlafaxine;   Dietary Supplement: Omega 3 Fatty acids;   Drug: Placebo (for Omega 3 fatty acid supplement)
Outcome Measures: Hospital Anxiety and Depression Scale;   Montgomery-Asberg depression rating scale (MADRS).;   short form health survey (SF-12);   visual analog scale for energy (VAS-E);   visual analog scale for pain (VAS-P);   Leeds sleep evaluation questionnaire (LSEQ)
6 Unknown  Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers
Condition: Healthy
Intervention: Drug: Desvenlafaxine succinate
Outcome Measures: The degree of norepinephrine reuptake in response to the increasing levels of the study medication will be assessed and compared between genders;   The degree of serotonin reuptake in response to the increasing levels of the study medication will be assessed and compared between genders
7 Unknown  Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine
Condition: Depression
Intervention: Drug: Desvenlafaxine
Outcome Measures: Sheehan Disability Scale (SDS);   Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Rating Scale- Anxiety (HAM-A), the Yale-Brown Obsessive Compulsive Scale (YBOCS), the Panic Disorder Severity Scale (PDSS), and the Penn Sate Worry Questionnaire (PSWQ).
8 Unknown  Effect of Antidepressants on White Matter Structure
Condition: Major Depression
Intervention: Drug: Desvenlafaxine
Outcome Measures: Anisotropy;   cognitive measures;   Pain threshold
9 Recruiting A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Sustained-Release Desvenlafaxine Hydrochloride;   Drug: Sustained-Release Venlafaxine Hydrochloride
Outcome Measures: Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17);   Change From Baseline on the Clinical Global Impression Scale;   Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Scale;   Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 10;   Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS);   Change From Baseline on the Visual Analogue Scale-Pain Intensity (VAS-PI);   Number of Participants in Remission Based on the HAM-D17 at Week 10
10 Recruiting A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release;   Drug: Placebo
Outcome Measures: Change from baseline to Week 8 in the Child Depression Rating Scale - Revised (CDRS-R): Total Score;   Clinical Global Impression Improvement (CGI-I) Score at the Week 8 visit;   Clinical Global Impression Severity Score at the Week 8 visit;   Clinical Global Impression Improvement Response (score 1 or 2)
11 Recruiting Neurocognition and Work Productivity in Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder
Intervention: Drug: desvenlafaxine
Outcome Measures: cognitive functioning as determined by neuropsychological testing;   work productivity as determined by rating scales
12 Recruiting Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities
Condition: Generalized Anxiety Disorder
Intervention: Drug: Desvenlafaxine
Outcome Measures: Mean changes in the Hamilton Anxiety Rating Scale from baseline visit to week 16.;   Mean change from baseline to week 16 on the measures of prefrontality including: Frontal System Behavioural Scale and Behaviour Rating Inventory of Executive Function-Adult
13 Recruiting A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Outcome Measures: Children's Depression Rating Scale, Revised (CDRS-R) total score change from baseline;   Clinical Global Impression Improvement (CGI I) score;   Clinical Global Impression Severity (CGI S) score change from baseline;   CGI I response (score of 1 or 2);   Remission on the CDRS-R (score ≤28)
14 Recruiting A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Outcome Measures: Children's Depression Rating Scale, Revised (CDRS-R) total score change from baseline.;   Clinical Global Impression -Improvement (CGI-I) score.;   Clinical Global Impression - Severity (CGI-S) score change from baseline.;   Clinical Global Impression - Improvement (CGI-I) response (score of 1 or 2);   Remission on the Children's Depression Rating Scale, Revised (CDRS-R) (score <=28)
15 Recruiting A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release;   Drug: fluoxetine;   Drug: placebo
Outcome Measures: Change from baseline to Week 8 visit in the Children's depression rating scale, revised (CDRS-R) total score;   Clinical Global Impression Improvement (CGI-I) score at the Week 8 visit;   CGI-S score change from baseline at the Week 8 visit;   CGI-I response (1 or 2)
16 Recruiting Effects of Treatment on Decision-making in Major Depression
Conditions: Major Depressive Disorder;   Healthy Controls
Intervention: Drug: Antidepressant
Outcome Measure: Money earned
17 Recruiting Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1
Conditions: Drug Metabolism;   Membrane Transport
Interventions: Drug: Drug application Amitriptyline;   Drug: Drug application Desvenlafaxine;   Drug: Drug application Sumatriptan;   Drug: Drug application Proguanil
Outcome Measures: Area under the plasma concentration-time curve (AUC) of the investigational drugs;   Total clearance, Cmax, Tmax, Mean AbsorptionTime, Alpha and Beta half-lives, Mean Residence Time (MRT) and Volume of distribution of the investigated drugs and their metabolites;   Dry mouth, fatigue, nausea, headache, vertigo, tinnitus, chills, anxiety and difficulties to read on Visual Analog Scales.;   Sedation on Stanford sedation scale;   Pupil diameter, latency, diameter at maximal constriction, amplitude and time for 33% recovery of initial pupil diameter measured by pupillometrie;   Genetic variants in OCT1, CYP2C19, CYP2D6 and MAO A
18 Recruiting Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT)
Condition: Major Depressive Disorder
Intervention: Drug: mixed salts amphetamine
Outcome Measures: Change in scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionaire;   Change in scores on the Montgomery Asberg Depression Rating Scale;   Change in scores on the Quick Inventory of Depressive Symptomatology Self Report 16

These studies may lead to new treatments and are adding insight into Pristiq etiology and treatment.

A major focus of Pristiq research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Pristiq